6197 related articles for article (PubMed ID: 35003131)
1. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
2. Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines-A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters.
Trimpert J; Herwig S; Stein J; Vladimirova D; Adler JM; Abdelgawad A; Firsching TC; Thoma T; Sehouli J; Osterrieder K; Gruber AD; Sawitzki B; Sander LE; Cichon G
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835096
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.
Keskin AU; Bolukcu S; Ciragil P; Topkaya AE
J Med Virol; 2022 Jan; 94(1):39-41. PubMed ID: 34536028
[No Abstract] [Full Text] [Related]
4. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
Strengert M; Becker M; Ramos GM; Dulovic A; Gruber J; Juengling J; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
EBioMedicine; 2021 Aug; 70():103524. PubMed ID: 34391096
[TBL] [Abstract][Full Text] [Related]
5. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
7. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM
Front Immunol; 2021; 12():742914. PubMed ID: 34659237
[TBL] [Abstract][Full Text] [Related]
8. Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination.
Paniskaki K; Anft M; Meister TL; Marheinecke C; Pfaender S; Skrzypczyk S; Seibert FS; Thieme CJ; Konik MJ; Dolff S; Anastasiou O; Holzer B; Dittmer U; Queren C; Fricke L; Rohn H; Westhoff TH; Witzke O; Stervbo U; Roch T; Babel N
Front Immunol; 2022; 13():816220. PubMed ID: 35145522
[TBL] [Abstract][Full Text] [Related]
9. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
10. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
[TBL] [Abstract][Full Text] [Related]
11. Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort.
Vo HTM; Maestri A; Auerswald H; Sorn S; Lay S; Seng H; Sann S; Ya N; Pean P; Dussart P; Schwartz O; Ly S; Bruel T; Ly S; Duong V; Karlsson EA; Cantaert T
Front Immunol; 2022; 13():817905. PubMed ID: 35185909
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.
Arroyo-Sánchez D; Cabrera-Marante O; Laguna-Goya R; Almendro-Vázquez P; Carretero O; Gil-Etayo FJ; Suàrez-Fernández P; Pérez-Romero P; Rodríguez de Frías E; Serrano A; Allende LM; Pleguezuelo D; Paz-Artal E
J Clin Immunol; 2022 Feb; 42(2):240-252. PubMed ID: 34787773
[TBL] [Abstract][Full Text] [Related]
14. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
15. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
Huang X; Yan Y; Su B; Xiao D; Yu M; Jin X; Duan J; Zhang X; Zheng S; Fang Y; Zhang T; Tang W; Wang L; Wang Z; Xu J
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215870
[TBL] [Abstract][Full Text] [Related]
16. Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies.
Amodio D; Ruggiero A; Sgrulletti M; Pighi C; Cotugno N; Medri C; Morrocchi E; Colagrossi L; Russo C; Zaffina S; Di Matteo G; Cifaldi C; Di Cesare S; Rivalta B; Pacillo L; Santilli V; Giancotta C; Manno EC; Ciofi Degli Atti M; Raponi M; Rossi P; Finocchi A; Cancrini C; Perno CF; Moschese V; Palma P
Front Immunol; 2021; 12():727850. PubMed ID: 34671350
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
[TBL] [Abstract][Full Text] [Related]
18. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
Front Immunol; 2022; 13():829665. PubMed ID: 35154152
[TBL] [Abstract][Full Text] [Related]
20. A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.
Kim E; Weisel FJ; Balmert SC; Khan MS; Huang S; Erdos G; Kenniston TW; Carey CD; Joachim SM; Conter LJ; Weisel NM; Okba NMA; Haagmans BL; Percivalle E; Cassaniti I; Baldanti F; Korkmaz E; Shlomchik MJ; Falo LD; Gambotto A
Eur J Immunol; 2021 Jul; 51(7):1774-1784. PubMed ID: 33772778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]